Tempest Therapeutics (TPST)
(Delayed Data from NSDQ)
$1.35 USD
-0.06 (-4.26%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Balance Sheet
Fiscal Year End for Tempest Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 39 | 31 | 52 | 39 | 64 |
Receivables | 0 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 2 | 17 | 2 | 6 |
Total Current Assets | 40 | 33 | 69 | 41 | 71 |
Net Property & Equipment | 1 | 1 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 1 |
Total Assets | 52 | 46 | 73 | 43 | 75 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 3 | 5 | 18 | 6 | 9 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 4 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 9 | 7 | 20 | 8 | 13 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 6 | 10 | 15 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 28 | 37 | 10 | 15 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 192 | 154 | 136 | 278 | 267 |
Retained Earnings | -165 | -136 | -100 | -245 | -209 |
Other Equity | 0 | 0 | 0 | 1 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 27 | 18 | 36 | 34 | 60 |
Total Liabilities & Shareholder's Equity | 52 | 46 | 73 | 43 | 75 |
Total Common Equity | 27 | 18 | 36 | 34 | 60 |
Shares Outstanding | 19.25 | 10.52 | 6.90 | 1.20 | 1.20 |
Book Value Per Share | 1.39 | 1.72 | 5.23 | 28.11 | 49.89 |
Fiscal Year End for Tempest Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 31 | 32 | 39 | 11 | 18 |
Receivables | 0 | 0 | 0 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 0 | 1 | 1 | 1 | 1 |
Total Current Assets | 32 | 34 | 40 | 12 | 19 |
Net Property & Equipment | 1 | 1 | 1 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 42 | 44 | 52 | 24 | 31 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 1 | 1 | 1 | 1 | 1 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 4 | 2 | 3 | 3 | 3 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 9 | 7 | 4 | 2 | 3 |
Total Current Liabilities | 15 | 11 | 9 | 7 | 9 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 2 | 4 | 6 | 8 | 7 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 25 | 24 | 25 | 25 | 26 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 200 | 194 | 192 | 157 | 156 |
Retained Earnings | -183 | -173 | -165 | -158 | -151 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 17 | 21 | 27 | -1 | 5 |
Total Liabilities & Shareholder's Equity | 42 | 44 | 52 | 24 | 31 |
Total Common Equity | 17 | 21 | 27 | -1 | 5 |
Shares Outstanding | 20.84 | 22.22 | 19.20 | 13.30 | 11.50 |
Book Value Per Share | 0.81 | 0.93 | 1.39 | -0.09 | 0.44 |